# US 10,308,693 B2 · Antimicrobial peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,308,693 B2
- Document ID: US10308693B2
- Status: Granted
- Kind: B2
- Application number: 15/115,161
- Filed: 2016-02-17
- Published: 2016-12-15
- Granted: 2019-06-04
- Earliest claimed: 2015-02-22
- Assignees: Omnix Medical Ltd.
- Applicants: Omnix Medical Ltd.
- Inventors: Niv Bachnoff; Moshe Cohen-Kutner
- Web page: https://patentgrep.com/patent/US10308693B2

## CPC

- C07K 14/43563: {from insects}
- A61K 38/1767: {from invertebrates}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/43536: {from worms}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides a peptide comprising: a core amino acid sequence, which is identical or similar to the amino acid sequence of a member of the Cecropin family. The invention further provides a nucleic acid sequence encoding the peptide and a vector comprising said nucleic acid. The invention further provides a pharmaceutical composition comprising said peptide or said nucleic acid. The invention further provides methods of treating an infection, overcoming inherent or acquired resistance of a microorganism to an antibiotic agent or disinfecting a wound, the methods comprises administering the peptide to a subject in need thereof.

## Claims

### Claim 1

A cyclic peptide that has an amino acid sequence having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 6.

### Claim 2 (depends on 1)

The cyclic peptide of claim 1, wherein the peptide is as set forth in SEQ ID NO:6.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising the cyclic peptide of claim 1.

### Claim 4 (depends on 1)

A method of treating a bacterial infection, the method comprising administering the cyclic peptide of claim 1 to a subject in need thereof, wherein the bacterial infection is caused by gram negative bacteria.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutical composition is in a form of a liquid, cream, gel, paste, powder, emulsion, an ointment, a liniment, a lotion, a transdermal system, an injection fluid, a suspension, a film patch or spray.

### Claim 6 (depends on 3)

The pharmaceutical composition of claim 3, which is in the form of a capsule or a tablet.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the cyclic peptide of claim 1 in conjunction with one or more anti-inflammatory active agents.

### Claim 8 (depends on 1)

A method of overcoming inherent or acquired resistance of a gram negative bacteria to an antibiotic agent, comprising: contacting the gram negative bacteria with the cyclic peptide of claim 1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the gram negative bacteria is a member of Enterobacteriaceae spp., Pseudomonas spp. Salmonella spp., or Acinetobacter spp., or any combination thereof.

### Claim 10 (depends on 1)

A method of disinfecting a cutaneous abscess comprising contacting the cutaneous abscess with the cyclic peptide of claim 1, wherein the infection in the cutaneous abscess is caused by gram negative bacteria.

### Claim 11 (depends on 1)

The cyclic peptide according to claim 1, wherein the amino acid sequence has at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 6.